| 主权项 |
1. A crystalline form of Nilotinib hydrochloride selected from the group consisting of
a) crystalline form T20 of Nilotinib hydrochloride characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at 5.3, 7.0, 14.4, 20.1, and 21.1 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 1; an X-ray powder diffraction pattern substantially as depicted in FIG. 2; and combinations thereof; b) crystalline form T27 of Nilotinib hydrochloride characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at 6.8, 11.8, 12.6, 13.7, and 25.3 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 68; and combinations thereof; c) crystalline form T28 of Nilotinib hydrochloride characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at 4.2, 8.5, 11.3, 12.8, and 16.0 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 69; and combinations thereof; and d) crystalline form T29 of Nilotinib hydrochloride characterized by data selected from the group consisting of: an X-ray powder diffraction pattern having peaks at 6.0, 6.4, 8.9, 19.7, and 20.6 degrees two theta ±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 70; and combinations thereof. |
